Patritumab Deruxtecan
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Colorectal Cancer
Conditions
Metastatic Colorectal Cancer
Trial Timeline
Sep 14, 2020 → Feb 3, 2022
NCT ID
NCT04479436About Patritumab Deruxtecan
Patritumab Deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Metastatic Colorectal Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04479436. Target conditions include Metastatic Colorectal Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Colorectal Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05620914 | Phase 2 | Withdrawn |
| NCT06941272 | Phase 1/2 | Recruiting |
| NCT06596694 | Phase 1/2 | Recruiting |
| NCT05865990 | Phase 2 | Active |
| NCT04479436 | Phase 2 | Terminated |
| NCT02980341 | Phase 1/2 | Completed |
Competing Products
20 competing products in Metastatic Colorectal Cancer